ArticleComputational and structural biotechnology journal2025
Stage-specific gene pair ratios highlight genes and mechanisms related to presymptomatic and symptomatic Multiple Myeloma.
Article in Computational and structural biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/aim: Multiple Myeloma (MM) is the second most common blood cancer, characterised by the accumulation of malignant plasma cells and the production of large amounts of a monoclonal immunoglobulin protein, in the bone marrow. The identification and progression/behaviour of molecular markers across stages remains a scientific challenge. This work aims to provide a holistic approach in the understanding of the disease progression through a computational approach, capable of characterising and distinguishing disease stages. Materials and methods: Stage-stratified MM transcriptomic datasets were used to mine stage-specific information and calculate key entities at the gene level by means of: (a) differentially expressed genes (DEGs), (b) monotonically expressed genes (MEGs), (c) ratios of MEG-related pairs of genes (RMEGs). The performance of the RMEGs across samples has been investigated regarding their ability to characterize and discriminate the MM stages. The genes participating in the top-ranked RMEGs were further used for pathway enrichment analysis to further enlighten the functional understanding per MM stage. Results: We show that the proposed computational methodology by means of RMEGs reveals short lists of key genes across stages, which in turn highlight significant groups of pathways associated with regulation and cell cycle. Conclusion: We integrate the traditional analysis of DEGs with the concepts of MEGs and RMEGs, creating a novel computational approach capable of identifying key genes and pathways that can serve as a highly-filtered pool of candidate MM stage identification markers for further experimental investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.